Common Side Effects of Kimmtrak
Kimmtrak (tebentafusp-tebn), approved for treating HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, causes side effects in most patients. The most frequent ones, affecting over 30% of users in clinical trials, include nausea (66%), rash (63%), fever (60%), chills (57%), fatigue (57%), dry skin (53%), and decreased appetite (53%). These often occur early in treatment, especially after the first infusion, and may lessen over time.[1][2]
Serious Side Effects and Risks
Serious reactions hit about 10% of patients, including cytokine release syndrome (CRS, 0.9% severe), hypotension (9%), and capillary leak syndrome (8%). CRS symptoms like fever, low blood pressure, and breathing issues typically start within 24 hours of infusion. Other notable risks: liver toxicity (elevated enzymes in 60%), skin reactions (9% severe), and infections (due to immune effects). The FDA requires a REMS program for monitoring these.[1][3]
How Side Effects Are Managed
Doctors premedicate with steroids, acetaminophen, and antihistamines to reduce CRS and infusion reactions. Dose adjustments or delays handle ongoing issues like liver enzyme spikes or grade 3+ skin problems. Patients should report symptoms like swelling, dizziness, or jaundice immediately. In trials, 91% continued treatment despite side effects, with 6% discontinuing.[1][2]
Side Effects by Infusion Timing
Reactions peak after the first three weekly doses (0.1 mg/m² escalating to 20 then 30 mg/m²), then monthly at 185 mg/m². Early cytokine storms are common but rare later. Long-term monitoring flags ongoing skin, eye, or endocrine issues.[1]
Patient Experiences and Comparisons
Real-world reports echo trial data, with nausea and fatigue as top complaints on forums. Compared to checkpoint inhibitors like ipilimumab, Kimmtrak's profile is more infusion-tied but potentially less chronic neuropathy. No head-to-head trials exist.[2][4]
What Happens If Side Effects Occur
Mild cases resolve with supportive care; severe ones may need hospitalization for fluids or oxygen. Fatalities from CRS or liver failure are rare (<1%). Always consult prescribing info or oncologist for personalized risks.[1][3]
[1]: Kimmtrak Prescribing Information (FDA)
[2]: IMCgp100-202 Trial Data (NEJM)
[3]: FDA REMS for Kimmtrak
[4]: Drugs.com User Reviews